
Looking to sell OpenEvidence stock or options?
OpenEvidence is the developer of an AI-driven information platform designed to organize medical knowledge, enhancing its usefulness, accessibility, and clarity. The company's platform provides a curated database of journal content, sophisticated medical AI search capabilities, and tools for patient documentation, empowering healthcare professionals to make evidence-based decisions and improve patient outcomes. By utilizing OpenEvidence, healthcare providers can access pertinent research and enhance their care decision-making process.










Brian Sheth, Minetta Brook Capital, Jim Breyer, TF Capital (Trumbull), Endurance Global Ventures, Xfund, Global Alternative Investment Management, BOND Capital (San Francisco), Byers Capital Investment Advisory, Okeanos (United States).
/PRNewswire/ -- OpenEvidence, America's most widely used medical knowledge platform, today announced EvidenceGrade, a new feature that grades and visualizes,...
Read more/PRNewswire/ -- OpenEvidence, the most widely used medical AI and clinical decision-support platform among U.S. physicians, today announced the launch of...
Read morePrint NORWELL, Mass. and MIAMI, March 12, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) and OpenEvidence today announced a new partnership to expand access to trusted, expert-reviewed rare disease information for clinic...
Read more/PRNewswire/ -- On March 10, 2026, for the first time in history, one million clinical consultations were conducted between NPI verified physicians and an AI...
Read moreOpenEvidence Inc., a startup that develops artificial intelligence software for physicians, today disclosed that it has raised $250 million in funding.Thrive Capital and DST Global led the investm
Read moreOpenEvidence, an AI startup whosetools are used by U.S. physicians, has raised $250 million infresh funding at a $12 billion valuation, the Nvidia and GoogleVentures-backed company said on...
Read more